MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research

Key Points

• MiNK Therapeutics was downgraded by Zacks Research from a "hold" rating to a "strong sell" rating, reflecting a negative outlook from analysts.
• Despite receiving mixed ratings from other analysts, the average consensus rating is "Moderate Buy" with a price target of $37.50.
• The company's stock recently reported a significant earnings miss, posting ($1.06) EPS compared to the expected ($0.55), indicating financial struggles.

Zacks Research cut shares of MiNK Therapeutics (NASDAQ:INKT - Free Report) from a hold rating to a strong sell rating in a report issued on Monday, August 18th,Zacks.com reports.

A number of other analysts also recently issued reports on INKT. William Blair downgraded MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 11th. B. Riley raised MiNK Therapeutics to a "strong-buy" rating in a report on Friday, July 18th. Finally, HC Wainwright raised MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 price target for the company in a report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.50.

MiNK Therapeutics Stock Performance

Shares of NASDAQ:INKT traded down $0.11 during trading on Monday, hitting $14.79. The company's stock had a trading volume of 15,278 shares, compared to its average volume of 402,183. The business has a 50 day moving average price of $14.65 and a two-hundred day moving average price of $10.41. The company has a market capitalization of $66.85 million, a PE ratio of -5.14 and a beta of 0.33. MiNK Therapeutics has a fifty-two week low of $4.56 and a fifty-two week high of $76.00.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.51). As a group, equities analysts expect that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.